Tokyo, Japan

Mercian Corporation


USPTO Granted Patents = 40

% Expired Patents = 32.5


Trademarks = 3

Forward Citations = 151

Loading Chart...
Loading Chart...

101 inventors (with patents filed for the assignee):

goldMedal Takeo Yoshioka (21 out of 41 patents)

silverMedal Takashi Nakashima (13 out of 22 patents)

bronzeMedal Kunio Isshiki (10 out of 16 patents)

4.  Toshio Tsuchida (9 out of 15 patents)

5.  Kazuyuki Dobashi (7 out of 9 patents)

6.  Rokuro Okamoto (6 out of 20 patents)

7.  Mitsuo Nagai (5 out of 28 patents)

8.  Tomohiro Sameshima (5 out of 7 patents)

9.  Takao Narita (5 out of 5 patents)

10.  Hiroshi Tone (5 out of 13 patents)

11.  Jun Niijima (4 out of 25 patents)

12.  Masashi Yoshida (4 out of 9 patents)

13.  Yoshihiko Kotake (4 out of 26 patents)

14.  Susumu Takeda (4 out of 6 patents)

15.  Naoto Kawamura (4 out of 7 patents)


Core Competencies:
Hydroxylation
Macrolide Antibiotics
Physiologically Active Substances
Optically Active Compounds
Dihydropyridine Derivatives
Steroids Production
Antitumor Agents
Crystalline Antibiotics
Gene Encoding Proteins
Cyclodextrin Production
Osteoclast Differentiation Inhibitors
Azetidinone Derivatives

40 patents:

Mercian Corporation, based in Tokyo, specializes in the development and production of advanced macrolide compounds and physiologically active substances. The company focuses on innovative research in heterocyclic macrolides and isocoumarin derivatives, contributing to the field of osteoclast differentiation inhibitors and dihydroxycholesterol. With a commitment to biological production processes, Mercian plays a significant role in the pharmaceutical and biotechnology sectors, enhancing therapeutic options through its cutting-edge technologies.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Mercian Corporation
40 Patents

#933 in Tokyo

#1,978 in Japan

#17,048 in the World

Tokyo, JP
Tokyo, Japan
Forward Citations = 151

101 inventors:

Please report any incorrect information to [email protected]
Loading…